EMA Application withdrawn: Upkanz (Deferiprone) — Apotex B.V.

View source ↗

Summary

The EMA has withdrawn the application for Upkanz (deferiprone) by Apotex B.V. for Pantothenate Kinase-Associated Neurodegeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pantothenate Kinase-associated Neurodegeneration

Drugs mentioned

• Upkanz (deferiprone)

Snippet

Status: Application withdrawn. Therapeutic area: Pantothenate Kinase-Associated Neurodegeneration. MAH: Apotex B.V.. Orphan medicine